Literature DB >> 31087195

Dyskinesia in multiple system atrophy and progressive supranuclear palsy.

Wolfgang H Jost1, Paul Lingor2, Lars Tönges3,4, Johannes Schwarz5, Carsten Buhmann6, Jan Kassubek7, Anette Schrag8.   

Abstract

In the differential diagnosis of Parkinson syndromes, the response to L-Dopa is an essential criterion for the diagnosis of idiopathic Parkinson's syndrome (IPS), and the presence of L-Dopa-induced dyskinesia (LID) is considered a supportive criterion. This implies that in the presence of LID an atypical Parkinson-syndrome (APS) is unlikely. However, dyskinesia, and in particular LID, can also be present in APS such as MSA and PSP, although less frequently, and with varying clinical appearance. We conclude that whilst presence of dyskinesia provides support for a diagnosis of IPD, they do not allow reliable differentiation from APS.

Entities:  

Keywords:  Dyskinesia; Multiple system atrophy; Parkinson’s disease; Progressive supranuclear palsy

Year:  2019        PMID: 31087195     DOI: 10.1007/s00702-019-02012-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  66 in total

1.  Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates.

Authors:  N Ginovart; L Farde; C Halldin; C G Swahn
Journal:  Synapse       Date:  1999-02       Impact factor: 2.562

Review 2.  Coupling of dopamine receptor subtypes to multiple and diverse G proteins.

Authors:  A Sidhu; H B Niznik
Journal:  Int J Dev Neurosci       Date:  2000-11       Impact factor: 2.457

Review 3.  Dyskinesia: L-dopa-induced and tardive dyskinesia.

Authors:  O Rascol; N Fabre
Journal:  Clin Neuropharmacol       Date:  2001 Nov-Dec       Impact factor: 1.592

4.  Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.

Authors:  A W Dunah; Y Wang; R P Yasuda; K Kameyama; R L Huganir; B B Wolfe; D G Standaert
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

5.  No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment.

Authors:  Vito Sanci; Sylvain Houle; Jean N DaSilva
Journal:  Can J Physiol Pharmacol       Date:  2002-01       Impact factor: 2.273

Review 6.  Animal models of acute drug-induced akathisia - a review.

Authors:  P S Sachdev; M Brüne
Journal:  Neurosci Biobehav Rev       Date:  2000-05       Impact factor: 8.989

7.  Dystonia in multiple system atrophy.

Authors:  S M Boesch; G K Wenning; G Ransmayr; W Poewe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

8.  Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment.

Authors:  M Geurts; E Hermans; J M Maloteaux
Journal:  Eur J Pharmacol       Date:  1999-10-08       Impact factor: 4.432

Review 9.  Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

Authors:  S Fahn
Journal:  Arch Neurol       Date:  1999-05

Review 10.  Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia.

Authors:  J L Vitek; M Giroux
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

View more
  2 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

2.  Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies.

Authors:  Giovanni Palermo; Eleonora Del Prete; Ubaldo Bonuccelli; Roberto Ceravolo
Journal:  J Neurol       Date:  2020-06-27       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.